A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft Recipients
Table 1
Baseline recipient and donor characteristics of the FAS population.
TAC/DAC
TAC/STR
Recipient age, mean (SD)
53.1 (9.6)
55.3 (6.5)
Male, no. (%)
49 (73.1)
45 (66.2)
Mean (SD) MELD score
16.2 (6.3)
14.5 (6.1)
HCV genotype:
1
7 (12.1)
5 (8.3)
1a
8 (13.8)
4 (6.7)
1b
28 (48.3)
37 (61.7)
2
1 (1.7)
1 (1.7)
2a/c
1 (1.7)
0
3
4 (6.9)
5 (8.3)
3a
6 (10.3)
7 (11.7)
4
2 (3.4)
1 (1.7)
4a
1 (1.7)
0
HCV-RNA positive*, no. (%)
50 (84.7)
55 (94.8)
Serum HCV-RNA, median (min; max) IU/mL
5.05 (0.95; 6.61)
5.09 (0.95; 6.12)
Donor age, mean (SD) years
49.1 (19.0)
50.6 (19.3)
Donor age <60 years, mean (SD) years
41 (61.2)
47 (64.7)
Donor age ≥60 years, mean (SD) years
26 (38.8)
24 (35.3)
Donor sex, male, no. (%)
43 (64.2)
32 (47.1)
Traumatic cause of donor death, no. (%)
21 (33.3)
20 (30.8)
Non-traumatic cause of donor death, no. (%)
42 (66.7)
45 (69.2)
Ischemic time, mean (SD), hours
8.8 (3.3)
8.0 (3.0)
Donor/recipient CMV serological status:
Donor +/recipient −, no. (%)
8 (11.9)
6 (8.8)
ABO identical, no. (%)
66 (98.5)
64 (94.1)
SD: standard deviation; HCV: hepatitis C virus; MELD: mean model for end-stage liver disease; CMV: cytomegalovirus.
*HCV-RNA above the limit of quantification at baseline.
